Related Experiment Video
Updated: Jul 18, 2025

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Safety profile of paediatric COVID-19 vaccines: An analysis of the US Vaccine Adverse Event Reporting System
Victoria Nikitina1, Greta Santi Laurini1, Nicola Montanaro2
1Unit of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
Insights
COVID-19 vaccine safety in children is supported by data showing most adverse events following immunization were non-serious. This analysis of US pediatric reports confirms the safety profile of authorized COVID-19 vaccines in this age group.
Area of Science:
- Pediatric Vaccinology
- Public Health Surveillance
- Immunology
Background:
- The safety of COVID-19 vaccines in pediatric populations requires ongoing evaluation.
- Spontaneous reporting systems are crucial for monitoring vaccine safety post-authorization.
Purpose of the Study:
- To assess the safety profile of COVID-19 vaccines in US children aged 0-17 years.
- To analyze adverse events following immunization (AEFI) and specific serious events like myocarditis and Guillain-Barré Syndrome.
Main Methods:
- Descriptive analysis of AEFI reports from the Vaccine Adverse Event Reporting System (VAERS) from December 2020 to November 2022.
- Focus on pediatric population (0-17 years) receiving authorized COVID-19 vaccines.
- Calculation of reporting rates for serious AEFIs, particularly after mRNA vaccines.
Main Results:
- Over 52,000 reports were analyzed, with the majority concerning Pfizer-BioNTech and Moderna mRNA vaccines.
- Most reported AEFIs were non-serious and consistent with product labeling.
- Serious AEFIs constituted a small fraction, with 96% linked to Pfizer-BioNTech; 91% of all reports involved children aged 6-17 years.
Conclusions:
- The study reinforces the safety of authorized COVID-19 vaccines in children.
- Reported adverse events were predominantly non-serious and listed in the respective product's Summary of Product Characteristics (SPCs).
- This analysis contributes to the evidence base for pediatric COVID-19 vaccination safety.
Aim:
To provide further evidence on the safety profile of COVID-19 vaccines in paediatrics by analysing the spontaneous reports of adverse effects related to these vaccines.
Methods:
Reports related to US paediatric population (from 0 to 17 years) vaccinated with authorised COVID-19 vaccines were extracted from Vaccine Adverse Event Reporting System from December 2020 to 17 November 2022. We conducted a descriptive analysis of Adverse Events Following Immunization (AEFI), calculating reporting rate of serious AEFIs and focusing on myocarditis and Guillain-Barré Syndrome after mRNA COVID-19 vaccines.
Results:
Overall, 52 720 reports were retrieved: 77% (40541)-Pfizer-BioNTech, 19% (10083)-Moderna, a small proportion for other vaccines 4% (2096). Most of AEFIs were non-serious and listed in corresponding SPCs. Of serious AEFIs, 96% were related to the Pfizer-BioNTech vaccine. Roughly 91% (47874) were related to people from 6 to 17 years, a small percentage of 9% (4773) to the younger group (0-5 years). In both groups, most of the reports were related to mRNA vaccines and the percentage of AEFIs experienced by females were similar to males.
Conclusions:
Data showed that events most frequently reported were non-serious and listed in the corresponding SPCs, extending the evidence of safety of COVID-19 vaccines authorised in the United States in children.
More Related Videos
09:03Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Teratogenicity
Relative Risk
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Vaccinations
Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...